Skip to content
DataLookout
Menu

NCT06806033

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 23 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words
  2. Notable Primary completion pushed from Jan 31, 2027 to Jul 31, 2029
    • Study completion pushed from Mar 30, 2029 to Jul 31, 2030
    • Site details revised at 7 of 53 sites
  3. Notable Eligibility criteria expanded, about 41 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised at 5 of 53 sites
  4. Notable Eligibility criteria expanded, about 119 wordsv22 Show 5 more changesShow less
    • Enrollment increased: 100 → 130 participants
    • Trial arms changed: 1 → 2
    • Secondary endpoints: 8 to 9
    • Primary endpoint revised
    • Study title shortened, about 14 words
  5. Minor Site details revised at 2 of 53 sitesv21
Show 17 earlier versionsHide 17 earlier versions
  1. Minor Site details revised at 5 of 53 sitesv20
  2. Minor Site details revised at 2 of 53 sitesv19
  3. Minor Study sites: 52 to 53v18
  4. Minor Study sites: 51 to 52v17
  5. Minor Study sites: 50 to 51v15
  6. Notable Eligibility criteria expanded, about 20 words
    • Study sites: 48 to 50
    • Secondary endpoints: details revised at 6 of 8 entries
    • Study title revised
    v13
  7. Minor Site details revised at 1 of 48 sitesv12
  8. Minor Study sites: 45 to 48v11
  9. Minor Study sites: 34 to 45v10
  10. Minor Study sites: 26 to 34
    • Study completion date: Mar 31, 2029 to Mar 30, 2029
    v9
  11. Minor Study sites: 19 to 26v8
  12. Minor Study sites: 16 to 19v7
  13. Minor Study sites: 10 to 16v6
  14. Minor Study sites: 8 to 10v5
  15. Minor Study sites: 7 to 8v4
  16. Minor Study sites: 3 to 7
    • Start date changed from estimate of Mar 31, 2025 to Mar 5, 2025
    v3
  17. Minor Study sites: 2 to 3
    • Primary completion date: Mar 31, 2027 to Jan 31, 2027
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Cytokine Release Syndrome (CRS)
Timeframe: Up to approximately 5 years

Secondary (9)

Incidence of Serious Cytokine Release Syndrome (CRS) Events
CRS Frequency Relative to the Start of Glofitamab Infusions
Incidence and Severity of Adverse Events (AEs)
Complete Response (CR) Rate as Determined by Independent Review Facility (IRF) and the Investigator
Overall Response Rate (ORR) as Determined by IRF and the Investigator
Show 4 moreShow less
Duration of Response (DOR)
Duration of Complete Response (DOCR)
Progression-Free Survival (PFS) as Determined by the IRF and the Investigator
Overall Survival (OS)

Arms and interventions

Cohort A: Glofit-GemOx Combination therapyExperimental

Participants with R/R aggressive B-cell Non-Hodgkin's Lymphoma will receive obinutuzumab pre-treatment, followed by glofitamab + gemcitabine + oxaliplatin, followed by glofitamab monotherapy. NOTE: Cohort A has been closed for recruitment.

Cohort B: Glofitamab MonotherapyExperimental

Participants with R/R aggressive B-cell Non-Hodgkin's Lymphoma will receive obinutuzumab pre-treatment, followed by glofitamab monotherapy.

Drugs: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin

Sites

53 sites in 7 countries

United States 33, France 5, Italy 5, Germany 4, South Korea 3, Canada 2, Australia 1